The government has so far paid Emergent BioSolutions $271 million, even though American regulators have yet to clear a single dose of vaccine produced at its manufacturing plant in Baltimore.
The government has so far paid Emergent BioSolutions $271 million, even though American regulators have yet to clear a single dose of vaccine produced at its manufacturing plant in Baltimore.